Interestingly, the early changes at the RNA level seen after bimiralisib exposure are largely overlapping with what was observed after exposing the same DLBCL cell lines to the p100δ inhibitor idelalisib, the p100δ/ p100γ inhibitor duvelisib, or the BTK inhibitor ibrutinib [75], in accordance with studies that were performed in normal B cells after BTK and PI3K genetic silencing [100]. This evidence concerns the gene PIK3CG and diffuse large B-cell lymphoma.